As Delta Plus Variant Identified, Changes To India’s Trials Policy Could Help

Serum/AZ COVID-19 Vaccine Interval Could Be Revised

As a new Delta plus variant is identified, India’s exemption of bridging trials for imported COVID-19 vaccines could help speed up immunization efforts. The urgency to fully immunize individuals could also prompt a reduction in the interval between Serum/AstraZeneca’s COVID-19 vaccine doses

New Coronavirus variant outbreak and covid-19 virus cell mutation
Policy Flexibility Is The Need Of The Hour As Coronavirus Changes It Colors

As if the Delta variant wasn’t enough, a Delta plus variant of SARS-CoV-2 has been recently identified and while it’s only causing the scientific community to take note as of now, it could soon cause governments across the world to hasten their immunization efforts.

On 13 June, clinician and scientist at Delhi's CSIR-Institute of Genomics and Integrative Biology (IGIB), Vinod Scaria tweeted "One of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Vaccines

More from Pink Sheet

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.